Abstract
The BRAF inhibitor (BRAFi) vemurafenib improves survival of patients with melanoma with BRAF(V600E) mutations. However, effects of sustained BRAFis on......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
